| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
As a fluorescent dye, Lissamine rhodamine B does not have a traditional biological target. Instead, it binds non-specifically to cellular structures or is conjugated to specific molecules for targeted labeling. Its fluorescence properties allow for the visualization and tracking of cellular processes, protein labeling, and tissue staining. It can be used as a fluorescent probe to measure the fluorescence anisotropy and fluorescence polarization (FA/FP) of competitive aptamers.
|
|---|---|
| ln Vitro |
To find ochratoxin A (OTA), a common mycotoxin, utilize Lissamine Rhodamine B (1 mg; 1 h; room temperature; covered from light) [1]. The fluorescence features of Lissamine Rhodamine B can be detected under the following conditions: fluorescence emission spectrum detection at 580 nm and excitation wavelength of 555 nm[1].
In vitro, Lissamine rhodamine B is used as a fluorescent probe for various applications. It is employed to stain cellular structures or molecules for visualization under fluorescence microscopy. The dye's bright red fluorescence makes it suitable for tracking cellular processes, protein labeling, and tissue staining. It is also used in flow cytometry and other assays that require fluorescent detection. Its ability to bind to specific targets or cellular components allows researchers to study cellular dynamics and molecular interactions. |
| ln Vivo |
Lissamine Rhodamine B is a radioactive tracer that can be utilized in positron emission tomography (PET) imaging of tumors in mice [2].
In vivo, Lissamine rhodamine B can be used as a radiotracer for imaging tumors in mice by positron emission tomography (PET). Its fluorescent properties also make it useful for in vivo imaging applications, where it can be used to track the distribution of labeled molecules or cells. The compound's bright red fluorescence allows for sensitive detection in biological tissues. |
| Enzyme Assay |
In vitro assays using Lissamine rhodamine B typically involve its use as a fluorescent probe. For example, it can be used to measure the fluorescence anisotropy and fluorescence polarization (FA/FP) of competitive aptamers. The dye's fluorescence can be detected using a fluorometer or a fluorescence microscope. Its binding to cellular structures can be visualized and quantified using imaging techniques.
|
| Cell Assay |
In vitro cell-based assays for Lissamine rhodamine B involve staining cells for fluorescence microscopy or flow cytometry. Cells are incubated with the dye, and its uptake and localization are visualized. The dye can also be conjugated to antibodies or other molecules for specific labeling of cellular targets. Its fluorescence is used to track cellular processes, such as endocytosis or protein trafficking.
|
| Animal Protocol |
In vivo animal studies for Lissamine rhodamine B are conducted for imaging applications. The compound is administered to mice, and its distribution is visualized using PET or fluorescence imaging. It can be used as a radiotracer for imaging tumors. The compound's fluorescence allows for real-time monitoring of its distribution and accumulation in tissues.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Lissamine rhodamine B are relevant for its use as an imaging agent. Its molecular weight is 558.67 g/mol. The compound is typically stored as a powder at room temperature. Its solubility and stability in biological fluids are important factors for its in vivo applications. Further details on its half-life and clearance are available from the primary research literature.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Lissamine rhodamine B has been evaluated in the context of its use as a dye and imaging agent. It is generally considered safe for laboratory use at standard concentrations. However, as with all chemicals, it should be handled with care. The compound is for research use only and is not intended for human consumption.
|
| References |
|
| Additional Infomation |
Additional information: Lissamine rhodamine B has the CAS number 2609-88-3. It is also known as 2-[3-(diethylamino)-6-diethylazaniumylidenexanthen-9-yl]-5-sulfobenzenesulfonate. The dye exhibits bright red fluorescence and is used in various biological and chemical research applications. It is a versatile tool for fluorescence microscopy, flow cytometry, and molecular imaging. This product is for research use only and is not approved for diagnostic or therapeutic applications.
|
| Molecular Formula |
C27H30N2O7S2
|
|---|---|
| Molecular Weight |
558.6663
|
| Exact Mass |
557.142
|
| CAS # |
2609-88-3
|
| Related CAS # |
3520-42-1 (hydrochloride salt)
|
| PubChem CID |
65191
|
| Appearance |
Brown to black solid powder
|
| Density |
1.2175 (rough estimate)
|
| Melting Point |
>300ºC(lit.)
|
| Index of Refraction |
1.6900 (estimate)
|
| LogP |
6.175
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
38
|
| Complexity |
1170
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
IOOMXAQUNPWDLL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C27H30N2O7S2/c1-5-28(6-2)18-9-12-21-24(15-18)36-25-16-19(29(7-3)8-4)10-13-22(25)27(21)23-14-11-20(37(30,31)32)17-26(23)38(33,34)35/h9-17H,5-8H2,1-4H3,(H-,30,31,32,33,34,35)
|
| Chemical Name |
2-[3-(diethylamino)-6-diethylazaniumylidenexanthen-9-yl]-5-sulfobenzenesulfonate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~5 mg/mL (~8.95 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7900 mL | 8.9498 mL | 17.8997 mL | |
| 5 mM | 0.3580 mL | 1.7900 mL | 3.5799 mL | |
| 10 mM | 0.1790 mL | 0.8950 mL | 1.7900 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| RECRUITING | NCT05559151 | Procedure: Remimazolam Benzenesulfonate |
Possible Molecular Mechanism of Remimazolam Benzenesulfonate Remimazolam Benzenesulfonate on Nenhanced Recovery After Surgery |
Zhonghua Chen,MD | 2023-01-01 | Not Applicable |
| NCT01091714 | COMPLETED | Dietary Supplement: Omega-3 Dietary Supplement: Omega-3 Dietary Supplement: Omega-3 |
Cardioprotective Levels | Bucci Laser Vision Institute | 2010-10 | Phase 4 |
| NCT05108220 | COMPLETED | Dietary Supplement: Cannabidiol (CBD)- containing consumer products | Anxiety Generalized Anxiety Disorder |
Radicle Science | 2020-10-15 | |
| NCT04138342 | UNKNOWN STATUS | Drug: Quantum dots coated with veldoreotide
Drug: Topical approved placebo |
Breast Cancer Skin Cancer Skin Diseases |
Al-Azhar University | 2019-09-15 | Phase 1 |
| NCT02550860 | TERMINATED | Drug: soybean oil (SO)-based IVFE (Medialipide) Drug: fish oil (FO)-containing IVFE (Lipidem) |
Intestinal Diseases | Hospices Civils de Lyon | 2015-01 | Phase 3 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
